title: Dronedarone for atrial fibrillation: a new therapeutic agent.
abstract: Atrial fibrillation is the most common of the serious cardiac rhythm disturbances and is responsible for substantial morbidity and mortality. Amiodarone is currently one of the most widely used and most effective antiarrhythmic agents for atrial fibrillation. But during chronic usage amiodarone can cause some serious extra cardiac adverse effects, including effects on the thyroid. Dronedarone is a newer therapeutic agent with a structural resemblance to amiodarone, with two molecular changes, and with a better side effect profile. Dronedarone is a multichannel blocker and, like amiodarone, possesses both a rhythm and a rate control property in atrial fibrillation. The US Food and Drug Administration approved dronedarone for atrial fibrillation on July 2, 2009. In this review, we discuss the role of dronedarone in atrial fibrillation.
authors.affiliation: Department of Cardiology, Chicago Medical School, Chicago, IL 60064, USA.
authors.forename: Pawan D
authors.initials: PD
authors.lastname: Patel
authors.forename: Rohit
authors.initials: R
authors.lastname: Bhuriya
authors.forename: Dipal D
authors.initials: DD
authors.lastname: Patel
authors.forename: Bhaskar L
authors.initials: BL
authors.lastname: Arora
authors.forename: Param P
authors.initials: PP
authors.lastname: Singh
authors.forename: Rohit R
authors.initials: RR
authors.lastname: Arora
mesh_terms: D000638:Amiodarone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy* / Q000503:physiopathology; D000077764:Dronedarone; D019317:Evidence-Based Medicine; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D000077764:Dronedarone; D000638:Amiodarone
references.citation: Am Heart J. 2008 Sep;156(3):527.e1-9
references.pmid: 18760136
references.citation: N Engl J Med. 2008 Jun 19;358(25):2678-87
references.pmid: 18565860
references.citation: J Cardiovasc Pharmacol. 2003 Feb;41(2):191-202
references.pmid: 12548079
references.citation: Br J Clin Pharmacol. 2007 Dec;64(6):785-91
references.pmid: 17662087
references.citation: N Engl J Med. 2007 Sep 6;357(10):987-99
references.pmid: 17804843
references.citation: J Cardiovasc Pharmacol. 2000 Dec;36(6):802-5
references.pmid: 11117382
references.citation: Eur Heart J. 2003 Aug;24(16):1481-7
references.pmid: 12919771
references.citation: J Cardiovasc Pharmacol. 2000 Sep;36(3):376-83
references.pmid: 10975596
references.citation: N Engl J Med. 2005 May 5;352(18):1861-72
references.pmid: 15872201
references.citation: Endocrinology. 2003 Feb;144(2):552-8
references.pmid: 12538616
references.citation: Ann Intern Med. 1994 Oct 1;121(7):529-35
references.pmid: 8067651
references.citation: Clin Endocrinol (Oxf). 2009 Jan;70(1):2-13
references.pmid: 18727707
references.citation: N Engl J Med. 2009 Feb 12;360(7):668-78
references.pmid: 19213680
references.citation: Br J Pharmacol. 2001 Jul;133(5):625-34
references.pmid: 11429385
references.citation: J Cardiovasc Pharmacol. 1995 Sep;26(3):453-61
references.pmid: 8583788
references.citation: Eur J Pharmacol. 1995 Jun 6;279(1):25-32
references.pmid: 7556379
references.citation: Circulation. 1999 Nov 30;100(22):2276-81
references.pmid: 10578003
references.citation: JAMA. 2001 May 9;285(18):2370-5
references.pmid: 11343485
references.citation: J Cardiovasc Pharmacol. 1995 Oct;26(4):570-6
references.pmid: 8569217
references.citation: J Cardiovasc Electrophysiol. 2003 Aug;14(8):885-90
references.pmid: 12890054
references.citation: N Engl J Med. 2009 Apr 30;360(18):1811-3
references.pmid: 19403901